Shire plc beats by $0.34, reports revs in-line; reaffirms FY17 EPS guidance, revs guidance (176.47)
- Reports Q1 (Mar) earnings of $3.63 per share, excluding non-recurring items, $0.34 better than the Capital IQ Consensus of $3.29; revenues rose 109.0% year/year to $3.57 bln vs the $3.54 bln Capital IQ Consensus.
- Co reaffirms guidance for FY17, sees EPS of $14.60-15.20 vs. $15.00 Capital IQ Consensus Estimate; sees FY17 revs of $14.5-14.8 bln vs. $15.23 bln Capital IQ Consensus Estimate.
- SHP643 for the treatment of HAE. The SHP643 open-label extension study completed enrollment in March 2017. Topline pivotal Phase 3 study results are expected in Q2 2017. SHP640 for the treatment of bacterial and adenoviral conjunctivitis. The global Phase 3 clinical development program will have clinical sites in over 20 countries. Patient recruitment has started and the first patient visit occurred in March 2017. The topline data is expected in Q2 2018.